Comparative Pharmacology
Head-to-head clinical analysis: LIQUAEMIN SODIUM PRESERVATIVE FREE versus SODIUM HEPARIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUAEMIN SODIUM PRESERVATIVE FREE versus SODIUM HEPARIN.
LIQUAEMIN SODIUM PRESERVATIVE FREE vs SODIUM HEPARIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin binds to antithrombin III, accelerating its inhibition of coagulation factors IIa (thrombin) and Xa, thereby preventing thrombus formation and extension.
Binds to antithrombin III, accelerating its inhibition of factor Xa and thrombin (factor IIa), thereby preventing fibrin formation and extension of thrombi.
Intravenous: Initial bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour; subcutaneous: 5000 units every 8-12 hours.
Initial IV bolus 80 units/kg followed by continuous IV infusion at 18 units/kg/hour; adjusted based on aPTT. Alternatively, subcutaneous: 333 units/kg loading dose then 250 units/kg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (0.5-1.5 h at therapeutic doses, dose-dependent due to saturable clearance). Context: shorter half-life in pulmonary embolism, prolonged in hepatic/renal impairment. Protamine reversal used for rapid offset.
Terminal elimination half-life is dose-dependent: 0.5-1.5 hours at low doses, 1.5-2.5 hours at high doses. Clinically, anticoagulant effect half-life is approximately 1-5 hours, with shorter half-life at lower doses.
Renal: 50-70% as unchanged heparin and metabolites via saturable clearance; biliary/fecal: <5% as metabolites.
Renal: negligible; primarily cleared by hepatic and reticuloendothelial system (desulfation and depolymerization). Unchanged drug not excreted in urine.
Category C
Category A/B
Anticoagulant
Anticoagulant